{"analyses":[{"ciLowerLimit":"-6.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-2.1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","paramType":"Mean Difference (Final Values)","paramValue":"-4.4","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.9","value":"-9.1"},{"groupId":"OG001","spread":"6.1","value":"-4.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"description":"The total pain reduction will be calculated by the (average of mouth and throat) area under the curve (AUC) adjusting for baseline, with time scale replaced by a numerical scale of 1,2,3,4,5,6. The numerical scale will be used rather than the raw time scale in order to give proper weights to more immediate patient-reported mouth pain outcomes after treatment. The AUC will be calculated by proration when there are terminal missing data. If the missing data are intermittent, simple imputation will be applied to calculate the AUC. The question ('On a scale from 0 to 10, what number best describes your MOUTH PAIN due to your radiation treatment now?') used 11-point numerical analog scales (0 (no pain) to 10 (worst pain imaginable or possible) scores) to measure pain. The AUCs for the two treatment arms were compared by using the Wilcoxon rank sum test with 95% CIs.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive (10 mg/mL x 2.5 mL) 25 mg doxepin hydrochloride (diluted to 5 mL with 2.5 mL of sterile water for irrigation, or sterile water for injection, or distilled water) oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.","id":"OG000","title":"Arm I (Doxepin-Placebo)"},{"description":"Patients receive 2.5 mL placebo (diluted to 5 mL with 2.5 mL of sterile water for irrigation, or sterile water for injection, or distilled water) oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm I on day 2.","id":"OG001","title":"Arm II (Placebo-Doxepin)"}],"paramType":"MEAN","populationDescription":"If a patient cancels, is missing baseline data, or only provides baseline data, he/she will be excluded from the statistical analysis. The primary analysis of the total pain reduction will only use primary data from the first phase.","reportingStatus":"POSTED","timeFrame":"Baseline and Day 1","title":"Total Pain Reduction (Mouth and Throat)","type":"PRIMARY","unitOfMeasure":"units on a scale"}